Department of Health and Aged Care publishes revised agenda for November 2022 PBAC meeting

Department of Health

18 October 2022 - Version 3 notes 9 amendments, including the withdrawal of a resubmission for a new medicine.

Amgen has withdrawn its submission for sotorasib (Lumakras) for certain patients with non-small-cell lung cancer.  Could we see a resubmission at a later date that includes the results from the CodeBreak 200 clinical trial? We shall have to wait and see. 

Read PBAC agenda (version 3)

Michael Wonder

Posted by:

Michael Wonder